JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Avatud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	6.8M -8.1M
Müük	33M 72M
Aktsiakasum	-0.04
Kasumimarginaal	-11.242
Töötajad	105
EBITDA	6.7M -5.4M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. märts 2026

Turustatistika
By TradingEconomics
Turukapital	55M 146M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2026, 00:00 UTC

Kuumad aktsiad

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4. veebr 2026, 22:55 UTC

Tulu

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4. veebr 2026, 21:44 UTC

Tulu

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4. veebr 2026, 21:39 UTC

Tulu

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5. veebr 2026, 00:00 UTC

Tulu

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5. veebr 2026, 00:00 UTC

Tulu

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4. veebr 2026, 23:45 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4. veebr 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4. veebr 2026, 22:59 UTC

Omandamised, ülevõtmised, äriostud

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4. veebr 2026, 22:30 UTC

Tulu

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4. veebr 2026, 22:30 UTC

Tulu

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4. veebr 2026, 22:21 UTC

Tulu

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4. veebr 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4. veebr 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4. veebr 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4. veebr 2026, 21:53 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4. veebr 2026, 21:51 UTC

Tulu

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

4. veebr 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4. veebr 2026, 21:45 UTC

Tulu

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4. veebr 2026, 21:44 UTC

Tulu

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4. veebr 2026, 21:43 UTC

Tulu

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4. veebr 2026, 21:41 UTC

Tulu

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4. veebr 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4. veebr 2026, 21:30 UTC

Tulu

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4. veebr 2026, 21:30 UTC

Tulu

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4. veebr 2026, 21:30 UTC

Tulu

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.